Fatima Nogueira

Dr. Fatima Nogueira

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MMMarly M. Marques
Marly M. Marques
MCMonica R. F. Costa
Monica R. F. Costa
FFFranklin S. Santana Filho
Franklin S. Santana Filho
JVJosé L. F. Vieira
José L. F. Vieira
MNMargareth T. S. Nascimento
Margareth T. S. Nascimento
MAMaria G. C. Alecrim
Maria G. C. Alecrim
Data on chloroquine (CQ)-resistantPlasmodium vivaxin Latin America is limited, even with the current research efforts to sustain an efficient malaria control program in all these countries whereP. vivaxis endemic and where malaria still is a major public health issue. This study estimatedin vivoCQ resistance in patients with uncomplicatedP. vivaxmalaria, with use of CQ and primaquine simultaneously, in the Brazilian Amazon. Of a total of 135 enrolled subjects who accomplished the 28-day follow-up, parasitological failure was observed in 7 (5.2%) patients, in whom plasma CQ and desethylchloroquine (DCQ) concentrations were above 100 ng/dl. Univariate analysis showed that previous exposure to malaria and a higher initial mean parasitemia were associated with resistance but not with age or gender. In the multivariate analysis, only high initial parasitemia remained significant. Hemoglobin levels were similar at the beginning of the follow-up and were not associated with parasitemia. However, at day 3 and day 7, hemoglobin levels were significantly lower in patients presenting CQ resistance. TheP. vivaxdhfr(pvdhfr),pvmrp1,pvmdr1, andpvdhpsgene mutations were not related to resistance in this small sample.P. vivaxCQ resistance is already a problem in the Brazilian Amazon, which could be to some extent associated with the simultaneous report of anemia triggered by this parasite, a common complication of the disease in most of the areas of endemicity.

1 June 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MCMarta P. Carrasco
Marta P. Carrasco
ANAna S. Newton
Ana S. Newton
Luís Miguel GoncalvesLuís Miguel Goncalves
Luís Miguel Goncalves
AGAna Góis
Ana Góis
MMMarta Machado
Marta Machado
RMRui Moreira
Rui Moreira

1 April 2003 in Molecular and Cellular Probes
Verified
Journal Article
Closed access
JGJ.P. Gil
J.P. Gil
Fatima NogueiraFatima Nogueira
Fatima Nogueira
JSJ. Strömberg-Nörklit
J. Strömberg-Nörklit
JLJ. Lindberg
J. Lindberg
MCM. Carrolo
M. Carrolo
VRV.E. Rosário
V.E. Rosário

1 May 2004 in Infection and Immunity
Verified
Journal Article
Closed access
SBSébAstien Bagot
SébAstien Bagot
Fatima NogueiraFatima Nogueira
Fatima Nogueira
ACAlexis Collette
Alexis Collette
VRVirgilio Do Rosario
Virgilio Do Rosario
FLFrançoIs Lemonier
FrançoIs Lemonier
ILInès Leleu
Inès Leleu
To obtain insight into the mechanisms that contribute to the pathogenesis ofPlasmodiuminfections, we developed an improved rodent model that mimics human malaria closely by inducing cerebral malaria (CM) through sporozoite infection. We used this model to carry out a detailed study on isolated T cells recruited from the brains of mice during the development of CM. We compared several aspects of the immune response related to the experimental model ofPlasmodium bergheiANKA infection induced by sporozoites in C57BL/6 mice and those related to a blood-stage infection. Our data show that in both models, oligoclonal TCRVβ4+, TCRVβ6+, TCRVβ8.1+, and TCRVβ11+major histocompatibility complex class I-restricted CD8 T cells were present in the brains of CM+mice. These CD8+T cells display an activated phenotype, do not undergo apoptosis, secrete gamma interferon or tumor necrosis factor alpha, and are associated with the development of the neurological syndrome.

23 December 2013 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DMDaniela Miranda
Daniela Miranda
RCRita Capela
Rita Capela
IAInês S. Albuquerque
Inês S. Albuquerque
PMPatrícia Meireles
Patrícia Meireles
IPIsa Paiva
Isa Paiva
FLFrancisca Lopes
Francisca Lopes

6 August 2014 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ELElsa Lobo
Elsa Lobo
BSBruno de Sousa
Bruno de Sousa
SRSoraia Rosa
Soraia Rosa
PFPaula Figueiredo
Paula Figueiredo
LLLis Lobo
Lis Lobo
Fatima NogueiraFatima Nogueira
Fatima Nogueira
Mozambique implemented artemisinin-based combinations therapy (ACT) using artemether-lumefantrine (AL) as the first-line treatment for uncomplicated malaria in 2009. AL remains highly efficacious, but widespread use may soon facilitate emergence of artemisinin tolerance/resistance. The prevalence of pfmdr1 different alleles in Maputo and Mozambique is not known, either after or before the introduction of ACT. Pfmdr1 molecular markers related to Plasmodium falciparum susceptibility were analysed before and after transition to ACT. A first group of samples was collected between June 2003 and June 2005 and a second group in the period between March 2010 and March 2012. Three alleles were analysed by PCR-RFLP: N86Y, Y184F and D1246Y, in the pfmdr1 gene. Alleles N86, 184F and D1246 increased from 19.5, 19.6 and 74.4% in 2003–2005 to 73.2, 22.7 and 96.7% in 2010–2012, respectively. After implementation of ACT (2010–2012), pfmdr1 haplotypes, either two- and three-codon basis, were generally less diverse than before the implementation of ACT (2003–2005). The prevalence of haplotypes N86-184Y, N86-D1246 and 184Y-D1246 increased from 12,2, 27.3 and 71.7% in 2003–2005 to 59.4, 84.3 and 78.6% in 2010–2012. The three-codon basis haplotypes NFD and NYD also increased significantly during the same period. The alleles N86 and 184 F and the triple haplotype N86-184 F-D1246 showed a significantly increased prevalence after introduction of ACT.